NCT00077285View on ClinicalTrials.gov

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Sarcoma
Interventions
BIOLOGICAL

filgrastim

DRUG

carboplatin

DRUG

cyclophosphamide

DRUG

dexrazoxane hydrochloride

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

ifosfamide

DRUG

irinotecan hydrochloride

DRUG

vincristine sulfate

PROCEDURE

conventional surgery

RADIATION

radiation therapy

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER